276
Background:
Patients receiving immunotherapy frequently experience cancer-related fatigue, symptom burden, and impaired health-related quality of life (HRQOL). Although exercise can improve patient-reported outcomes, the mechanisms underlying its effects remain unclear; this study evaluated whether reductio...
P. G. Bergerot, C. Bergerot, P. W. Schorn et al.· JCO Oncology Practice· 0 citations
BACKGROUND
Tumor mutational burden (TMB) has been established as a predictor of response to immune checkpoint inhibitors (ICI) ± chemotherapy in advanced non-small cell lung cancer (NSCLC). However, less is known about its role as a predictor of immune-related adverse events (irAEs) METHODS: This monocentric cohort stu...
F. Pecci, Xinan Wang, Valentina Santo et al.· Journal of Thoracic Oncology· 0 citations
A multidisciplinary panel of oncology experts convened to review current evidence gaps, controversies, and unmet needs in the management of lung cancer, highlighting the need for prospective, head‐to‐head clinical trials.
N. Florez, S. Patel, R. Salgia et al.· Cancer· 0 citations
A descriptive analysis of oncology trials registered on ClinicalTrials.gov is presented and strategies to enhance international collaboration and amplify LMIC participation in setting global cancer research priorities are proposed.
O. Arrieta, E. Rios-Garcia, Cittim B. Palomares-Palomares et al.· The Oncologist· 0 citations
A complex germline architecture underlying susceptibility and molecular subtype in young-onset lung cancer is delineated, consistent with additive risk from rare and common variants.
J. LoPiccolo, Ryan L. Collins, Noah Fields et al.· medRxiv· 0 citations
RAS alterations mediate resistance to targeted agents in approximately 10% of oncogene-driven lung cancer, and Rational combinations with novel RAS inhibitors are effective in preclinical models, providing the basis for their clinical investigation and extending the paradigm of precision oncology.
F. Facchinetti, L. Friboulet, L. Liao et al.· Annals of Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.